SCHEMBL1015519

SCHEMBL1015519

N#Cc1cc(Cl)ccc1NC(=O)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 7/20 0.47
ALDH1A1 P00352 7/20 0.47
HPGD P15428 4/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 5/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GLA P06280 2/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALOX12 P18054 1/20 0.45
APAF1 O14727 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CRHR1 P34998 1/20 0.44
ATM Q13315 1/20 0.43
TRPV1 Q8NER1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8103369 0.83 GAA (0.58) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL11184124 0.81 NPC1 (0.63) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL404789 0.81 HPGD (0.47) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL4293229 0.79 KDM4E (0.48) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL13102688 0.79 KCNMA1 (0.60) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL21319206 0.79 RAB9A (0.60) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL11320230 0.79 ALDH1A1 (0.44) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL10376952 0.78 MEN1 (0.53) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL5337611 0.77 KMT2A (0.54) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL30644771 0.77 KMT2A (0.54) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034464-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-10 US disclosed
EP-2271624-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034464-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF ADRA1D, ADRB1, ADRB2 MEN1 818/4885KMT2A 2082/4885KDM4E 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.